Latent Tuberculosis Infection Clinical Trial
Official title:
Performance Evaluation of the VIDAS TB-IGRA Assay.
NCT number | NCT04048018 |
Other study ID # | B2694-CTPR |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | December 5, 2019 |
Est. completion date | June 30, 2021 |
Verified date | July 2021 |
Source | BioMérieux |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will evaluate the performance of the VIDAS® Interferon Gamma (IFN-γ) Release Assay (TB-IGRA) assay, which is intended for use as an aid in the diagnosis of tuberculosis infection. This study is designed to assess (1) the sensitivity of this assay, (2) its percent agreement with other diagnostic tests, (3) its measurement precision , and (4) any potential interference of the presence of other non-tuberculosis mycobacterial bacterial infections with this assay.
Status | Completed |
Enrollment | 2401 |
Est. completion date | June 30, 2021 |
Est. primary completion date | June 30, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 2 Years and older |
Eligibility | Active TB Population Inclusion Criteria: A person classified as or suspected of having M. tuberculosis disease (active TB): A person with known HIV status, determined by a laboratory or rapid test performed no earlier than one month prior to, or at the time of inclusion into this study A person of age = 2 years Exclusion Criteria: A person who has been on an anti-TB treatment for >15 days for the ongoing infection Pregnant women A person who has received an anti-tumor necrosis factor (TNF) alpha treatment within the previous 3 months A person who has had prior TST A person with an NTM infection A person with positive HIV status. High Risk for TB infection Inclusion criteria : A person who is at increased risk for M. tuberculosis infection (and therefore LTBI) and/or for progression to active TB: A person with age = 2 years A person with known HIV status Non-inclusion criteria will be: A person who has or has had active TB A person who has received treatment for active TB or LTBI A person who has received an anti-TNF alpha treatment A person who has had a TST Pregnant women Person who has been an NTM infection Low Risk for TB Infection Inclusion criteria Generally healthy people, unlikely to have encountered TB disease in the past, that may be subject to TB testing for professional, academic or personal reasons (e.g.: students, healthcare personnel and healthcare volunteers, military recruits) A person with age = 18 years old Non-inclusion criteria A person who is considered at high risk for LTBI A person who has or has had active TB A person who has received treatment for active TB or LTBI A person who has received an anti-TNFalpha treatment A person who has had a TST Pregnant women A person who has been diagnosed with a NTM infection NTM population: Inclusion criteria A person who is positive for NTM of interest confirmed by culture and identification; Non-inclusion criteria A person who has been on antibiotic treatment for NTM; A person with confirmed active TB; A person with HIV; A person with a history of active TB; A person who have received treatment for LTBI; A person who is at high risk for LTBI Pregnant women. Precision Population Inclusion criteria: A person previously enrolled in the Active TB, High Risk or Low Risk studies, or a blood donor. Non-inclusion criteria An adult who was not previously enrolled in the Active TB, High Risk or Low Risk studies except for blood donors For blood donors only: A person who can be classified as being at increased risk for M. tuberculosis infection (and therefore LTBI) and/or for progression to active TB |
Country | Name | City | State |
---|---|---|---|
Brazil | Universidade Federal de Mato Grosso do Sul (UFMS) | Campo Grande | |
Brazil | Universidade Federal Da Grande Dourados (UFGD) | Dourados | |
France | Anti-TB center of Chambéry | Chambéry | |
France | Lapeyronie Hospital | Montpellier | |
France | Anti-TB center of Nanterre | Nanterre Cedex | |
France | Avicenne Hospital | Paris | |
France | Lariboisière Hospital | Paris | |
France | North Hospital | Saint-Étienne | |
Georgia | National Center for Tuberculosis and Lung Disease | Tbilisi | |
India | Hinduja Hospital | Mumbai | |
Italy | INMI L. Spallanzani | Rome | |
Mexico | Autonomous University of Baja California | Mexicali | |
South Africa | TASK Applied Science, Delft Day Hospital Premises | Cape Town | |
South Africa | University of Cape Town Centre for Lung Infection and Immunity | South Africa | |
United Kingdom | Evelina London Children's Hospital | London | |
United Kingdom | Royal Free Hospital | London | |
United Kingdom | St Thomas' Hospital | London | |
United States | University of Illinois- Chicago | Chicago | Illinois |
United States | Naional Jewish Health | Denver | Colorado |
United States | University of Florida | Gainesville | Florida |
United States | Rutgers University | Newark | New Jersey |
United States | Stanford University | Palo Alto | California |
United States | Saint Louis University | Saint Louis | Missouri |
United States | UC San Diego | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
BioMérieux |
United States, Brazil, France, Georgia, India, Italy, Mexico, South Africa, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Positive, negative, indeterminate for tuberculosis | The VIDAS or comparator assays will qualitatively determine the presence or absence of Mycobacterial TB infection in a participant's blood. This measurement is based on the level of interferon gamma released after stimulation of T cells in blood. | One-time measurement through study completion for each participant, an average of 5 months. | |
Primary | Sensitivity and positive and negative percent agreement for the VIDAS TB IGRA assay with comparator assay | Results obtained using the VIDAS assay will be compared with the results obtained from other methods. | One-time measurement through study completion for each participant, an average of 5 months. | |
Primary | Degree of Interference by nontuberculous mycobacteria for the VIDAS TB IGRA assay | Persons with NTM will be tested using the VIDAS TB IGRA. | One-time measurement through study completion for each participant, an average of 5 months. | |
Primary | Measurement Precision of the VIDAS TB IGRA assay results | 6- 4mL blood samples will be collected from each participant and tested using different VIDAS instruments. | Triplicate measurement per sample through study completion, an average of 5 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04094012 -
Risk of SDRs Under 3HP and 1HP Regimen for LTBI
|
Phase 3 | |
Completed |
NCT01582711 -
Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT
|
Phase 3 | |
Recruiting |
NCT06033807 -
Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients
|
||
Completed |
NCT01622140 -
Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis
|
||
Completed |
NCT00557765 -
Use of a Gamma-IFN Assay in Contact Tracing for Tuberculosis in a Low-Incidence, High Immigration Area
|
N/A | |
Completed |
NCT00463086 -
Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons
|
N/A | |
Active, not recruiting |
NCT01398618 -
Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)
|
Phase 3 | |
Recruiting |
NCT00905970 -
Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection
|
N/A | |
Recruiting |
NCT00449345 -
Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis
|
N/A | |
Completed |
NCT02641106 -
VDOT for Monitoring Adherence to LTBI Treatment
|
N/A | |
Completed |
NCT00804713 -
Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits
|
N/A | |
Completed |
NCT01136161 -
Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection
|
Phase 2 | |
Recruiting |
NCT03312647 -
Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection
|
N/A | |
Completed |
NCT02810678 -
Enhancing the Public Health Impact of Latent Tuberculosis (TB) Infection Diagnosis and Treatment
|
N/A | |
Completed |
NCT01223534 -
QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.
|
Phase 4 | |
Withdrawn |
NCT00558480 -
Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis
|
N/A | |
Recruiting |
NCT00692809 -
Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection
|
N/A | |
Completed |
NCT03702049 -
Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV
|
N/A | |
Terminated |
NCT01761201 -
"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".
|
Phase 3 | |
Completed |
NCT01608685 -
Interferon Gamma Release Assays (IGRA) Testing Versus Tuberculin Skin Test in Renal Transplant Recipients
|
N/A |